No announcement yet.

FDA: COMPANY ANNOUNCEMENT Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid? (Thyroid Tablets, USP) Due to Super Potency

  • Filter
  • Time
  • Show
Clear All
new posts

  • FDA: COMPANY ANNOUNCEMENT Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid? (Thyroid Tablets, USP) Due to Super Potency

    I've been seeing complaints about this brand since last year at this patient advocate website: I've read that most of the dessicated thyroid brands use product from Chinese pigs. There may be one brand that sources from US pigs.


    Company Announcement Date:May 22, 2020FDA Publish Date:May 22, 2020Product Type DrugsReason for Announcement:Super potency

    Company Name:Acella Pharmaceuticals, LLCBrand Name:Acella

    Product Description:30-mg, 60-mg and 90-mg NP Thyroid?

    Company Announcement

    Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid? (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The product may have up to 115.0% of the labeled amount of Liothyronine (T3).
    Risk Statement: Patients being treated for hypothyroidism (underactive thyroid), who receive superpotent NP Thyroid, may experience signs and symptoms of hyperthyroidism (overactive thyroid) which include, but are not limited to, weight loss, heat intolerance, fatigue, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. Pregnant women who take superpotent NP Thyroid may also experience negative maternal and fetal outcomes including miscarriage and/or impairment to fetal development. Patients should talk to their healthcare professional before they stop taking their NP Thyroid medicine. To date, Acella has received two reports of adverse events known to be related to this recall.
    NP Thyroid (thyroid tablets, USP) is composed of levothyroxine and liothyronine, and used to treat hypothyroidism (underactive thyroid). The products subject to recall are packed in 100-count bottles. See product images.
    To best identify the product, the NDC’s, Product Description, Lot Numbers and Expiration Dates are listed. These lots were distributed nationwide in the USA to Acella’s direct accounts.
    NP Thyroid 30 mg 42192-329-01 M329A19-1 20-Dec
    M329H18-1 20-Jul
    M329J18-1 20-Aug
    M329J18-2 20-Aug
    M329J18-3 20-Aug
    M329M18-2 20-Nov
    NP Thyroid 60 mg 42192-330-01 M330J18-2A 20-Aug
    M330J18-3 20-Aug
    NP Thyroid 90 mg 42192-331-01 M331G18-1 20-Jun
    M331J18-1 20-Aug
    M331J18-2 20-Aug
    M331M18-1 20-Nov
    M331M18-2 20-Nov
    Acella is proactively notifying its wholesalers by email and phone to discontinue distribution of the product being recalled and is arranging for return of all recalled products. Patients who are currently taking NP Thyroid from the lots being recalled should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.
    Consumers with questions about the recall can email Acella Pharmaceuticals at or contact Acella Customer Service at 1-800-541-4802, Monday through Thursday from 9:00 am to 5:00 pm ET and Friday from 9:00 am to 12:30 pm ET. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
    • Complete and submit the report Online
    • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
    Company Contact Information

    Consumers:Allen Fields, Senior Vice President, Clinical and Regulatory Affairs1-800-541-4802

    Product Photos
    • Content current as of:


    Ask Congress to Investigate COVID Origins and Government Response to Pandemic H.R. 834

    i love myself. the quietest. simplest. most powerful. revolution ever. ---- nayyirah waheed

    (My posts are not intended as advice or professional assessments of any kind.)
    Never forget Excalibur.